In this free webinar, gain insight into the antibody-drug conjugate (ADC) therapeutic landscape and pipeline. Attendees will be introduced to global site selection, preparedness and training required ...

In this free webinar, learn why antibody-drug conjugate (ADC) programs benefit from a "fail faster" approach to reduce late-stage attrition and accelerate development. Attendees will gain insight into ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar Objective responses and promising anti-tumor activity observed in ...

Antibody-Drug Conjugates (ADCs) are a fast-growing modality in both cancerous and non-cancerous indications. To date 15 ADCs have been approved by the regulatory agencies as therapies for various ...

Data from the study with the lead ADC candidate, HDP-101, show elimination of tumor cells in one patient Clinical data from IMS will be presented in R&D webinar on 15 October at 17:00 CEST / 11:00 EDT ...